Apogee Pharmaceuticals, Inc.

Weihe Pharma{grave Over (c)}euticals Co. Ltd.

Yunnan Weihe Pharmaceuticals Co. Ltd.

Kaiji Hu

Safwat Mohamed Rabea

David Earl Bogucki

Genhui Chen

Jianxiong Li

John M Webster

Bin Li

Kk Durgarao Viswanadham

Gopi Kishore Valluru

The present disclosure relates to fatty acid amide hydrolase (FAAH) modulators, inhibitors, or FAAH modulators and inhibitors and methods and uses thereof. The FAAH modulators, inhibitors, or FAAH modulators and inhibitors may be compounds having Formula I, II, III or IV. Pharmaceutical compositions comprising the FAAH modulators, inhibitors, or FAAH modulators and inhibitors are also provided.

Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof

Disclosed are compounds of Formula I that are useful as Monoacylglycerol lipase (MAGL) inhibitors These compounds may be used in pharmaceutical compositions, formulations, and methods for the treatment of disease states, disorders, and conditions benefited by the inhibition or modulation of MAGL activity, such as, but are not limited to, anxiety and mood disorder, metabolic disorder, a neurodegenerative disorder, mental disorder, brain disorder, pain, inflammatory disorder, cancer, Alzheimer's disease, movement disorders, epilepsy or stroke.

Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof

The invention is drawn to novel macrolide compounds of formula I having antibiotic and antineoplastic activities, useful as medicaments and/or agrochemicals for microorganism infections, in particularly for infectious diseases involving drug-resistant, and for treatment of human and animal cancers. 

Macrolide compounds with antibiotic and antineoplastic properties

Growing community of inventors

Burnaby, Canada

Kaiji Hu